

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973

Status	RECRUITING
Phase	Phase 2
Sponsor	Incyte Corporation
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (8)

- Aged 12 to < 18 years at the time of informed consent/assent signing.
- Body weight \geq 30 kg at both screening and baseline visits.
- Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
- Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
- HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.

... and 3 more (see full listing online)

Exclusion (4)

- Presence of $>$ 20 draining tunnels (fistulas) at either the screening or baseline visit.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
- Laboratory values outside of the protocol-defined ranges.

Locations (27 total)

University of Alabama At Birmingham, Birmingham, Alabama, United States
Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States
Saguaro Dermatology, Phoenix, Arizona, United States
... and 24 more locations